Vortioxetine for Major Depressive Disorder
Vortioxetine for Major Depressive Disorder
Vortioxetine is a multi-modal 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of the 5-HT transporter, and was approved 30 September 2013 by the US FDA for the treatment of MDD. This was based on a clinical development programme that included six positive 6–8 week studies, including one study in elderly people, and one positive maintenance study in adults. The most commonly observed AEs identified in the product label are nausea, constipation and vomiting. Vortioxetine represents another option for the treatment of MDD. Vortioxetine appears to have a favourable weight-gain profile. Additional information regarding the time course of response/remission and for the commonly occurring AE of nausea would be helpful to better characterise this agent. Pending clinical trials include those examining cognitive dysfunction that can accompany MDD.
Conclusions
Vortioxetine is a multi-modal 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of the 5-HT transporter, and was approved 30 September 2013 by the US FDA for the treatment of MDD. This was based on a clinical development programme that included six positive 6–8 week studies, including one study in elderly people, and one positive maintenance study in adults. The most commonly observed AEs identified in the product label are nausea, constipation and vomiting. Vortioxetine represents another option for the treatment of MDD. Vortioxetine appears to have a favourable weight-gain profile. Additional information regarding the time course of response/remission and for the commonly occurring AE of nausea would be helpful to better characterise this agent. Pending clinical trials include those examining cognitive dysfunction that can accompany MDD.
Source...